Seton Hall University

eRepository @ Seton Hall
Law School Student Scholarship

Seton Hall Law

5-1-2013

Comparative Effectiveness Research in the United
States: The Failures And What Can Be Done To Fix
It
John D. Barry

Follow this and additional works at: https://scholarship.shu.edu/student_scholarship
Recommended Citation
Barry, John D., "Comparative Effectiveness Research in the United States: The Failures And What Can Be Done To Fix It" (2013). Law
School Student Scholarship. 182.
https://scholarship.shu.edu/student_scholarship/182

Comparative Effectiveness Research in the United States: The Failures And What Can Be Done
To Fix It
By: John Barry'
I. Introduction
Each year over 750,000 vertebral fractures occur within the United States. 1 The
preferred treatment for such injuries is vertebroplasty, the injection of acrylic bone cement into
the affected vertebra. 2 Every year Medicare pays for 40,000 of these surgeries, each at a cost of
$3,000 or more. 3 While a common and established procedure, there is actually no evidence that
vertebroplasy or a number of related spinal procedures provide any benefit to patients above
what they receive from conservative treatment options such as bed rest or physical therapy. 4
Studies have shown that this surgery is no more effective than "fake," or placebo, surgeries
performed on those suffering from pain, and in fact, it can create additional risks for patients. 5
This is but one example of a serious problem within the American medical system: many
established medical treatments are performed or prescribed based on tradition, rather than
clinical evidence. 6 This often leads to wasted resources spent on treatments which provide little
or no benefit. 7 Comparative effectiveness research hopes to solve this problem.

• J.D. Candidate, 2013, Seton Hall University School of Law; B.A., 2005, University of Pennsylvania. I would like
to thank Professors John Jacobi and Frank Pasquale for their invaluable guidance and assistance with this comment.
I would also like to thank my comment editor, Eric Dante, for his patience.
1
David F. Kallmes et al., A Randomized Trial ofVertebroplasty for Osteoporotic Spinal Fractures, 361 NEW ENG. J.
MED. 569, 570 (2009); Scott Kinkade & James Stevermer, Vertebroplasty for Osteoporotic Fracture? Think Twice,
58 J. FAM. PRAC. 654, 654 (2009).
2
Kallmes, supra note l, at 569.
3
Robert Langreth, Common Spine Surgery Shows No Benefit, FORBES (Aug. 5, 2009, 05:00PM),
http://www.forbes.com/2009/08/05/vertebroplasty-healthcare-reform-business-healthcare-backpain.html.
4
!d. (quoting David Kallmes, the leader of the study, who says "Vertebroplasty as currently practiced in this countty
and around the world doesn't seem to work").
5
!d. (stating that patients who received the surgery had no increased functioning or decreased pain, while at the
same time had been exposed to increased risks inherent in surgical procedures).
6
MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE CONGRESS: REFORMING THE DELIVERY SYSTEM (2008),
available at http:// www.medpac.gov/documents/jun08_ entirereport.pdf (describing the existence of large gaps in
evidence between the way in which health care professionals treat patients and what clinical based evidence actually
shows is effective); see also Jerome Groopman, Why "Quality" Care Is Dangerous, WALL ST. J. (Apr. 8, 2009),
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Health care costs in the United States are increasing at an exponential rate. 8 Total health
expenditures in the United States have reached 2.5 trillion dollars per year. 9 The United States
surpasses every other country in the world in health care spending per capita. 10 However, this
vast spending has not led to a vastly healthier population. 11 While leading the world in costs, the
United States ranks 27th in the world for life expectancy of its citizens. 12 This is emblematic of
the fact that-no matter how hard a country may try to buy its way to health-increased
spending does not directly correlate to better health outcomes. 13
What is driving these extreme costs with low patient outcomes? While some might claim
that Americans on a whole are to blame for their poor health, 14 recent studies show that "health
burdens" that Americans cause themselves account for only a small percentage of total health
care costs. 15 The real answer is that health care costs are a multifaceted problem, with

http://online.wsj.com/article/SB123914878625199185.html (describing an old adage reportedly told to medical
students that "[h]alf of what we teach you is wrong- unfortunately we don't know which half').
7
See discussion infra Part V.
8
CTRS. FOR MEDICARE AND MEDICAID SERVS., NAT'L HEALTH EXPENDITURES 20 I 0, available at
https://www.cms.gov/Nationa!HealthExpendData/downloadslhighlights.pdf. Health care spending rose 3.9% in
2010, following a 3.8% increase in 2009. !d.
9
!d. As of the last accounting by the Centers for Medicare and Medicaid Services, this $2.6 trillion has accounted
for nearly 18% of the gross national product of the United States. !d.
10
Uwe E. Reinhardt eta!., U.S. Health Care Spending In An International Context, 23 HEALTH AFFAIRS 10, II
(2004). The United States spends nearly double the funds of the next highest spending country, Switzerland. !d.
11 !d.
12
!d. The average life expectancy in the United States is just over seventy seven years of age. !d. at 13. Ranking
directly behind the United States in 28th place for life expectancy is Cuba, which spends about 3% of what the
United States spends on health care every year. !d.
13
See Reinhardt, supra note 10.
14
See, e.g., Catharine Paddock, Obesity Healthcare Costs U.S. I 47 Billion Dollars A Year, New Study, MEDICAL
NEWS TODAY, Jul. 28, 2009, http://www.medicalnewstoday.com/articles/158948.php; Nanci Hellmic, Rising
Obesity Will Cost U.S. Health Care $344 Billion a Year, USA TODAY, Nov. 17,2011,
http://www.usatoday.com/news!health!weightloss/2009-ll-17-future-obesity-costs_ N.btm; Patrica McBroom,
$72. 7 Billion: Smokings Annual Health Care Cost, THE BERKELEYAN, Sept. 16, 1998,
http:/lherkeley.edu/news/herkeleyan/1998/0916/smoking.html.
15
Shubham Singhal eta!., How US Health Care Reform will Effect Employee Benefits, MCKINSEY Q, June 2011,
available at http://www.scribd.com/doc/57371828/McKinsey. This stndy states that while overall Americans are
more obese than other populations, Americans also consume both less tobacco products and less alcohol then other
economically developed countries. !d. The disease burden of the unhealthy American lifestyle is pegged at $25
billion a year, accounting for only 1% of the total cost of health care in the United States. !d.
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difficulties including availability, delivery, insurance coverage, and more. 16 However, one
approach that many developed nations have taken is to look closer at the pharmaceuticals and
medical treatments that drive up health care costs in their systems. 17 This Comment will focus
on comparative effectiveness research, one way in which the United States has chosen to combat
the rising costs seemingly inherent in pharmaceuticals and medical devices.
When the Food and Drug Administration (FDA) in the United States approves a drug or
treatment, the administration does it based solely on the two factors of drug safety and drug
efficacy. 18 The traditional FDA approval process relies mainly on a comparison of a single
treatment to a placebo. 19 In contrast, what has gained great favor in many other countries around
the globe is the use of comparative effectiveness research: the idea of evaluating treatments not
only to see if they work, but to see if they work better than currently available treatments. 20
Fortunately, this concept is gaining ground in the United States. 21 It holds the potential to have a
great impact on the American health care system because at the foundation of comparative
effectiveness research is the concept of providing better, clinically based treatments that in tum
lead to lower health care costs. 22

16

U.S. Health Care Costs, KAISER FAMILY FOUND. (2011), available at http://www.kaiseredu.org/lssueModules/US-Health-Care-Costs/Backgrouod-Brief.aspx.
17
Prescription Drug Costs, KAISER FAMILY FOUND. (20 II), available at http://www.kaiseredu.org/IssueModules/Prescription-Drug-Costs/Background-Brief.aspx ("The rise in costs of prescription medicines affects all
sectors ofthe health care industry").
18
21 C.F.R. § 314.94 (2011).
19
CATHY SCHOEN ET AL., BENDING THE CURVE: OPTIONS FOR ACHIEVING SAVINGS AND IMPROVING VALUE IN U.S.
HEALTH SPENDING, THE COMMONWEALTH FUND COMM'N ON A HIGH PERFORMANCE HEALTH SYSTEMS 19-21
(2007), available at http://www .commonwealthfund.org/Content/Publications/Fund-Reports/2007/Dec/Bending-theCurve--Options-for-Achieving -Savings-and-Improving-Value-in-U-S-Health-Spending.aspx
20
See discussion infra Part Ill.
21
SCHOEN, supra note 19.
22
!d. ("Better research leads to better treatments ... which leads to healthier patients ... and in tum a lower
economic burden on the health care system").
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Behind comparative effectiveness research is the idea that "what is newest is not always
best."23 By systemically comparing medications and medical devices, the hope is to find the
best, evidenced-based care. 24 By finding the most effective clinically backed treatments, health
care decision makers can treat their patients based on what actually works, without wasting time
or funds on ineffective treatments. The potential benefit is thus that by knowing the best
available treatment, care givers can provide better health outcomes, while at the same time save
money by not wasting resources on ineffective or less effective treatments. 25
Part II of this Comment provides a brief background on comparative effectiveness
research as it exists within the world of modern medical research. This part also provides a
background on the history of comparative effectiveness research as used within the United
States. It focuses on what the Patient Protection and Affordable Care Act,

26

the most recent

overhaul of the American health care system, has authorized this research to be used for, in
addition to what it may not be used for. Part III then explores the flaws contained in the
implementation of comparative effectiveness research as it is now currently authorized in the
United States. This Comment takes the position that as currently implemented, comparative
effectiveness research will have little effect on either patient outcomes or cost savings in the
American health care system. The current iteration of this program focuses on providing data
from comparative effectiveness research to physicians in hopes that they will use the information
in practice. This Comment takes the position that this use of information from comparative
effectiveness research will not be effective.
23

GRETCHEN JACOBSON, CONG. RESEARCH SERV., RL 31340, COMPARATIVE CLINICAL EFFECTIVENESS AND COSTEFFECTIVENESS RESEARCH: BACKGROUND, HISTORY, AND OVERVIEW I (2007).

!d.
!d. (stating the proposition that ineffective care is costly to the American health care system in many ways. Not
only are ineffective treatments themselves a waste of funds, the use of ineffective treatments may lead to lower
health outcomes by depriving patients of more beneficial treatments. Lower health outcomes in tum are costlier due
to that fact that these patients continue to seek treatment within the health care system).
26
Patient Protection and Affordable Care Act (PPACA) § 6301 (a), Pub. L. No. 111-148, 124 Stat. 119, 727 (20 I 0).
24
25

4

As a foil for what is being implemented in the United States, Part IV analyzes the health
care system of the United Kingdom. The United Kingdom is among the most prominent leaders

in implementation of comparative effectiveness research within a health care system. This Part
will analyze the cost-saving measures within the context of this foreign health care system and
will explain the benefits and downsides to the system.
Part V will explore the potential for integrating within the American system lessons
learned from the United Kingdom. It will discuss the difficulties in creating an effective system
of better care outcomes and cost savings. Both the social and political climate, which have
created fears of severe cost cutting and health care rationing, in addition to the potential for real
problems inherent in the use of comparative effectiveness research, create a difficult atmosphere
for comparative effectiveness to actually take hold. This Comment proposes that it is possible to
advance the current implementation of comparative effectiveness research in the United States,
creating positive health care outcomes and real-world cost savings. However, it should start
slow and pick the "low hanging fruit" of uncontroversial treatments, specifically avoiding endof-life care, so as to gamer acceptance within the patient population, society as a whole, and law
makers.
II. Overview of Comparative Effectiveness Research within the United States

A. Comparative Effectiveness Research as a form of Health Technology Assessment
Comparative effectiveness research is one branch of a larger tree known as health
technology assessment (HTA).Z 7 HTA is a field of study that looks to measure the value of
medical technologies such as pharmaceuticals and medical devices in terms of both their medical
and economic implications. 28 It serves to link the world of research-based findings to the world

27
28

JACOBSON, supra note 22. at 3.

Id at 4.
5

of clinical, in-practice decision making. 29 There are three main branches ofHTA prevalent in
the world today: comparative effectiveness research, cost-effectiveness analysis, and cost-benefit
analysis. 30
Comparative effectiveness research, although defined in many different ways, 31
essentially compares the effectiveness of two or more health care services or treatments? 2 It is
important to note that effectiveness, as defined here, is different from efficacy. Effectiveness is
the measure of the effect of a treatment in routine clinical practice. 33 In contrast, efficacy, the
measurement used by the FDA when approving a treatment, is the effect of the treatment under
optimal conditions? 4 By comparing competing treatments in real-world conditions, the hope is
to find the most effective treatment that leads to the best outcomes for patients. 35
Cost-benefit analysis and cost-effectiveness analysis are two ways of building upon
comparative effectiveness research by directly incorporating costs into the assessment of health
care technologies. 36 These two approaches both compare the cost of services to the additional
health benefits received. 37 They look to determine whether the additional health benefits, if any,
serve to justify additional costs? 8 Where the two approaches differ is on how the health benefits
are measured. In cost-benefit analysis, health benefits are valued in monetary terms, and the
results of each assessment are stated in terms of the monetary difference between treatment costs

!d.
U.S. NATIONAL LIBRARY OF MEDICINE, HTA 101 (2011), available at http://www.nlm.nih.gov/nichsr/hta!Ol/
tal0106.html.
31
See, e.g. COST-EFFECTIVENESS IN HEALTH AND MEDICINE (Martha Gold eta!. eds., 1996); PETER A. UBEL,
PRICING LIFE: WHY IT'S TIME FOR HEALTH CARE RATIONING (1999).
32
JACOBSON, supra note 22, at 4.
33 !d.
34
!d. at 5.
35
See SCHOEN, supra note 18.
36
!d. at 6.
37 !d.
38 !d.
29

30

6

and health benefits? 9 In cost-effectiveness analysis, health benefits are measured in nonmonetary units, with most systems using the unit of life years adjusted for quality, or quality
adjusted life years (QAL Y). 40 What is calculated is a ratio of costs and benefits, a showing of
the "cost-utility" of the treatment or pharmaceutical. 41 QALY is seen as, and often criticized for,
putting a spending cap on people's lives. 42
This Comment will focus on comparative effectiveness research and its potential within
the American health care system. Further, while other countries are implementing forms of costbenefit analysis and cost-effectiveness analysis,43 the social and political climate of America is
likely not ready for these direct cost-savings measures. 44 And while there may come a time
when the use of cost-benefit analysis or cost-effectiveness analysis need be further evaluated for
use in our system, this Comment proposes that comparative effectiveness research is the way to
gamer greater acceptance for HTA use in every day clinical decision making.
B. A History of Comparative Effectiveness Research in the United States
Comparative effectiveness research is not completely new to the United States. The
earliest government authorization of this form of research began at the state level with Oregon,
which has used comparative effectiveness in allocating resources to Medicaid recipients. 45 Also,
prior to this, private insurance companies and pharmaceutical manufacturers have used

39

Id. at 7.
Id; see also infra Part IV.
41
SCHOEN, supra note 18, at 12.
42
See infra Part V. The harsh criticism of a QALY -based system will be explored with an examination ofthe
United Kingdom's health system in this section.
43
See discussion infra Part V.
44
See discussion infra Part V; see also John K. Iglehart, The Political Fight Over Comparative Effectiveness
Research, 29 HEALTH AFF. 1757, 1758 (2010) (stating that comparative effectiveness is seen as akin to cost cutting
and many Americans feel that it is simply another way for insurers to limit care benefits).
45
OR. REv. STAT.§ 442.589 (2011); see also Somnath Saha et al., Giving Teeth to Comparative Effectiveness
Research~ The Oregon Experience, 362 NEW ENG. J. MED. El8(l) (20 l 0), available at
http://www.nejm.org/doi/pdfll 0 .l 056/NEJMp091293 8.
40

7

comparative effectiveness research to analyze medications and allocate resources to patients. 46
There has been little oversight of these studies, however, and next to no transparency as to
research methodologies.

47

Thus, these studies are viewed as skewed to the purely economic

interests of the sponsors rather than towards providing economically efficient care. 48
On the federal level, the Agency for Healthcare Research and Quality (AHRQ)49 had
previously been given limited powers to undertake comparative effectiveness efforts. The
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 50 provided a mere
$15 million per year in funding to AHRQ for research into comparative clinical effectiveness of
certain health care items and services. 5 1 Comparative effectiveness research finally gained real
force in 2009 with the creation of the Federal Coordinating Council for Comparative
Effectiveness Research. 52 This was a government body created by the massive American
Recovery and Reinvestment Act of2009, 53 a bill which primarily focused on stimulating
economic activity and job growth in the United States. 54 Over $1 billion was ear marked in the
legislation to go towards comparative effectiveness research within the United States. 55
This Federal Coordinating Council was short lived, however, as the sweeping health care
reform of the Patient Protection and Affordable Care Act (PPACA) created the Patient-Centered
Outcomes Research Institute (PCORI). 56 PCORI, unlike the Federal Coordinating Council

46

Steven Pearson, From Better Evidence to Better Care: Using Comparative Effectiveness Research to Guide
Practice and Policy, in BROOKINGS INST. IMPLEMENTING COMPARATIVE EFFECTIVENESS RESEARCH: PRIORITIES,
METHODS AND IMPACT 55 (2009).
47
!d. (explaining that private insurers often operate nnder a veil of secrecy with regards to their savings
methodologies).
"!d. at 57.
49
42 u.s.c. § 299 (2006).
50
Pub. L. No. 108-173, §1013(e), 117 Stat. 2066, 2438-41(2003)(codified at 42 U.S.C. §299b-7(e)(2006)).
5l !d.
52
American Recovery and Reinvestment Act of2009 § 804,42 U.S. C.§ 299b-8 (2010).
53
American Recovery and Reinvestment Act of2009, Pub. L. 111-5, tit. VII, 123 Stat. 115.
54 !d.
55 !d.
56
Patient Protection and Affordable Care Act (PPACA) § 630l(a), Pub. L. No. 111-148, 124 Stat. 119, 727 (2010).

8

before it, is a non-governmental entity. 57 When PPACA becomes effective in 2014, this private
non-profit organization will largely be comprised of private stakeholders: health care providers,
pharmaceutical manufacturers, health insurers, and patient representatives. 58 There will also be a
small number of government officials, such as representative from the National Institutes of
Health, on the board. 59
While the Federal Coordinating Council defined the original iteration of comparative
60

effectiveness research in use by the federal government, the definition as applicable to this
Comment comes from PP ACA. PPACA defines comparative effectiveness research as follows:
"The term[] 'comparative clinical effectiveness research' ... mean[ s] research evaluating and
comparing health outcomes and the clinical effectiveness, risks, and benefits oftwo or more
medical treatments, services, and items."61 These "medical treatments, services, and items"
include health care interventions, protocols for treatment, care management, and delivery,
procedures, medical devices, diagnostic tools, pharmaceuticals, integrative health practices, and
any other strategies or items being used in the treatment, management, and diagnosis of, or
prevention of illness or injury in, individuals. 62 Though comparative effectiveness research as
defined by PPACA may be seen as necessarily broad, 63 it also raises concerns with some that it

57

!d. This form of comparative effectiveness research is actually slightly different than was originally proposed.
The original House of Representatives version of the PPACA provided great strength to comparative effectiveness
research and what the govermnent was able to do with the data gained. Affordable Health Care for America Act,
H.R. 3962, lllth Cong. §1401(a)(2009).
58
§ 6301(a).
59
§ 6301(a), § 1181(!), 42 U.S.C. § 1320e(f); see also Press Release, U.S. Gov't Accountability Office, GAO
Announces Appointments to New Patient-Centered Outcomes Research Institute (PCOR/) Board of Governors,
(Sept. 23, 2010), available at http://www.gao.gov/press/pcori2010sep23.htrnl.
6
°FED. COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH, REPORT TO THE PRESIDENT AND
THE CONGRESS II (2009), available at http:// www.hhs.gov/recovery/prograrns/cer/cerannualrpt.pdf.
61
PPACA § 6302,42 U.S.C. § 299b-8 (2012).
62
63

!d.

Alan M. Garber & Harold C. Sox, Analysis & Commentary: The Role of Costs in Comparative Effectiveness
Research, 29 HEALTH AFF. 1805, 1805 (20 I 0) (stating the proposition that comparative effectiveness research
should be defined broadly in order to give PCORI the proper discretion in creating an effective program).
9

is simply poorly defined and thus does not give proper structure and guidance for an effective
clinical comparison system. 64
III. Comparative Effectiveness Research's Impact in United States

The main problem with the PP ACA version of comparative effectiveness research, and
the focus of this Comment, is that the legislation-emphasizes collection of data from comparative
effectiveness research as the end goal, rather than as a means to achieve cost-effective health
care options. 65 While PPACA established the PCORI and allocates $500 million in funding for
research, 66 it explicitly prohibits PCORI from having any decision-making power in regards to
"coverage, reimbursement or other policies for any public or private payer."67 Thus, though well
funded, the PCORI cannot develop practice guidelines, let alone make coverage
68
. .
determmatwns.

Further, the legislation severely hampers what the Secretary of the Department of Health
and Human Services may do with the findings ofPCORI. 69 Findings may not be used in any
way that may be construed as valuing the life of the young or non-disabled over the old or

64

Richard Saver, Health Care Reforms Wild Card: The Uncertain Effectiveness of Comparative Effectiveness
Research, !59 U. PA. L. REv. 2147, 2161 (2011) ("[l]mprecision creates considerable ambiguity during the critical
rollout phase of the new legislation. It also enables law makers to avoid, perhaps indefinitely, directly addressing
hard but critically important policy choices, such as whether comparative effectiveness research should look at
treatment costs.").
65

Kevin D. Frick, How Comparative Effectiveness Research Feeds into Cost-Benefit Analysis, 13 AM. MED. Ass'N
1. ETHICS 248, 249 (20 II) (stating the proposition that collection of data alone from comparative effectiveness
research is not enough to have a meaningful impact on the health care system).
66
PPACA § 630l(e), 26 U.S.C. § 9511; see also AM. Ass'N OF MED. COLLS., SUMMARY OF PATIENT-CENTERED
OUTCOMES RESEARCH PROVISIONS II (201 0). This report contains a summary the PCORI provisions within the
statute. See id.
67
PPACA § 630l(a), 26 U.S.C. § 9511.
68 !d.
69
CEA Registry Team, NICE Highlights Potential Cost-savings, THE CEA REGISTRY BLOG (May 7, 2010, 4:37PM)
https:l/research.tufts-nemc.org/cear4/Resources/CEARegistryBlog/tabid/69/
Entryld/48/NICE-highlights-potential-cost-savings.aspx (last visited Feb. 9, 2012) ("[L]anguage in the law places
limitations on the types of evidence that can be used to evaluate health care technologies, hampering the potential to
create a meaningful 'bending' of the healthcare cost-curve.").

10

terminally ill. 70 While this Comment does not advocate devaluing the life of any person, this
prohibition may be construed broadly to prohibit much of any cost savings. 71 The statute also
prohibits the Secretary from making Medicare coverage decisions based "solely" on data from
comparative effectiveness research. 72 In sum, these restrictions make it extremely hard for
Medicare and other government health care entities to use the data obtained from comparative
effectiveness studies in their care and coverage decisions. 73
Today, services and medications are approved for Medicare reimbursement so long as
they are deemed "reasonable and necessary."74 Medicare does have a provision that allows for
restricting payment to less costly alternative treatments but it goes unused. 75 At one time,
Medicare did attempt to use this policy to limit reimbursement of a medication due to existence
of a less-costly alternative, but it was struck down by the judiciary. 76 As such, Medicare has
since stopped applying this policy when processing reimbursement for drugs covered under
Medicare's Part B insurance program. 77 Further, Medicare has been extremely hesitant to deny

70

PPACA § 630 I (a}, 26 U.S.C. § 9511 ("[F]indings may not be used in such as manner that treats extending life of
an elderly, disabled, or terminally ill individual as of lower value than extending the life or an individual who is
younger, nondisabled or not terminally ill.").
71
Saver, supra note 63, at 2153 (discussing how this prohibition will likely be a strong deterrence against attempts
to limit many potentially ineffective care options primarily used by the elderly).
72
PPACA § 630l(c}, § 1182(b)(2), 42 U.S.C. § 1320e-l(b)(2).
73
Saver, supra note 63, at 2148 ("[L]awmakers have essentially defanged [comparative effectiveness research],
deploying it under conditions that will leave it underpowered.").
74
42 U.S.C. § 1395y(a)(l)(A}-{B).
75
!d. (Medicare provides reimbursement for treatments only up to the price of their "reasonably feasible and
medically appropriate" least costly alternatives.); see also MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE
CONGRESS: ALIGNING INCENTIVES IN MEDICARE 6-7 (2010).
76
Hays v. Sebelius, 589 F.3d 1279, 1280, 1283 (D.C. Cir. 2009). This cased involved Medicare's denial of
coverage for a treatment for chronic obstructive pulmonary disease. !d. The court found that Medicare's restriction

of reimbursement to an inexpensive medication rather than a more expensive alternative was unauthorized by that
statute. !d.
77
CMS Instructs Contractors to Rescind All LCA Provisions in Current LCDs, HEALTH POL'Y WKLY
(AmerisourceBergen Specialty Grp., Wash., D.C.), Apr. 30,2010, https://www.iononline.com/app/Documents/
Health%20Policy"/o20 Weekly /20 I 0/April%203 0,% 2020 I O.pdf.
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coverage for medications, and even when the FDA has explicitly deemed a medication
ineffective for treatment of a specific disease, 78 Medicare may still cover it for reimbursement. 79
Comparative effectiveness research that PPACA authorizes, in its current form, coupled
with Medicare's current policies, likely ensures that the money spent to gather data from
comparative effectiveness research will not save any Medicare funds. 80 It is worthy to note that
while PCORI is primarily focused on the public payer side, it does show some attention to
private health plans, but again fails to push any real innovation, as private health insurers have no
obligation to follow any of the findings ofPCORI and may do with the information as they see
fit. 81 The private insurers are unlikely to follow the findings ofPCORI without Medicare also
following suit. 82
Currently, the end result of the comparative effectiveness program that the PPACA
authorizes is to make the information available to physicians and hope that they take the
comparative effectiveness data into account when treating patients. 83 This use of the data faces
many hurdles, as doctors are unlikely to change their practices of their own accord. 84 First,
doctors, counter to what wonld commonly be assumed, do not base many of their practices on

78

Andrew Pollock, FDA Revokes Approval ofAvastinfor Use as Breast Cancer Drug, N.Y. TIMES, Nov. 18,2011,
http://www.nytimes.com/20 11/11/19/husiness/fda-revokes-approva1-of-avastin-as-breast-cancer-drug.html
79
Andrew Pollock, Medicare Will Pay for Avastin in Treating Breast Cancer, N.Y. TIMES, June 30,2011,
http://prescriptions.b1ogs.nytimes.com/20 11/06/30/medicare-will-pay-for-avastin-in-treating -breast-cancer/. A vas tin
was a FDA approved medication for the treatment of breast cancer, but after new evidence came to light that the
drug was ineffective for this treatment, the FDA removed its approval of the drug for breast cancer treatment. !d.
Despite new evidence of ineffectiveness and removal of FDA approval, Medicare still agreed to pay for the drug to
treat breast cancer. !d. The drug will cost Medicare $8,000 per patient, per month of treatment. !d.
80
Alexander K. Ommaya & Joel Kupersmith, Challenges Facing the US. Patient-Centered Outcomes Research
Institute, 306 JAMA, 756,756-66 (2011) ("[L]acking a substantial effort focused on implementation, the published
results of comparative effectiveness research are unlikely to change medical practice on their own.").
81
PPACA § 6301(a), § 11810), 42 U.S.C. § 1320eG) (2006).
82
Ommaya, supra note 79, at 757.
83
Saver, supra note 63, at 2150 (discussing how the information from the research will be made available to health
care professionals in hopes that they will use it in practice).
84
Ommaya, supra note 79, at 758 (explaining that physician care practices are extremely hard to change from within
the physician community itself); see also Saver, supra note 63, at 2150 ("What will be done with the information?
Not much. Many physicians seem unlikely to change clinical practice patterns, notwithstanding the outcomes of
[comparative effectiveness research] studies.").
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data-driven evidence. 85 Access to better evidence relating to clinical practices does not
necessarily translate into a change in real world practice. 86 For example, in 2007, the New
England Journal of Medicine published the "COURAGE" (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation) study. 87 The study showed that heart
surgery using stents to unclog blocked arteries, a common procedure, was no more effective than
treating the cardiac patients with drugs alone. 88 As a result of the study, it was thought there
would be a significant decrease in stent use. 89 However, stent usage has not declined. 90
Secondly, many other factors besides available information or evidence effects the
decisions that physicians make. Doctors often act based on how they are reimbursed for
procedures. 91 Marketing of pharmaceuticals and treatment options to physicians play a
significant role in the care given to patients. 92 Doctors also respond a great deal to patients'
requests for specific medications, which is in turn based on advertisements that patients see or
hear. 93 In addition, another important factor driving physician treatment decisions is fear of

85

See discussion supra note 6.
See William E. Boden, Optimal Medical Therapy With or Without PC! for Stable Coronary Disease, 356 NEW
ENG. J. MED. 1503 (2007).
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/d.

!d.
Keith Winstein, A Simple Health-Care Fix Fizzles Out, WALL ST. J., Feb. II, 2010, available at
http://online.wsj.com/article/SB I 000142405274870365210457465240 1818092212.html (discussing how stent
implants "are now back at peak levels" and that such studies "have rarely altered medical practice").
90
!d. Part of the reluctance to change may be because physicians (and hospitals) receive better reimbursement for
performing stent implants than for other treatments. !d.
91
David Hyman, Follow the Money: Money Matters in Health Care, Just Like in Everything Else, 36 AM. J.L. &
MED. 370, 381 (2010) ("It is difficult to overstate the extent to which economic incentives explain the structure,
J;',erformance, and pathologies of the American health care system.").
ELIZABETH DOCTEUR, How Will Comparative Effectiveness Research Affect the Quality of Health Care?: Timely
Analysis oflmmediate Health Policy Issues 5-6 (Urban Ins!. 2010); see also MARCIA ANGEL, THE TRUTH ABOUT
THE DRUG COMPANIES: HOW THEY DECEIVE Us AND WHAT TO DO ABOUT IT, 3-9 (2004) (describing how hundreds
of millions of dollars are spent bombarding doctors with targeted ads and in office pharmaceutical representatives
and the tremendous impact this has on the prescribing practices.)
93
See ANGEL, supra note 90. See also Ezekiel Emanuel, The Perfect Storm ofOverutilization, 299 J. AM. MED.
Ass. 2789,2790 (2008) (discussing how part of the overutilization of health care can be causally linked to direct-toconsumer marketing); Thorn Wilder, Despite Doubts About CER's Impact, Studies Should Take Place, Researcher
Says, 9 MED. REs. L. & POL'Y REP 216 (2010) (Doctors were slow to abandon a traditionally accepted breast cancer
treatment using a high-dose chemotherapy followed by bone marrow transplants in spite of mounting evidence of
88
89
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malpractice liabilities. 94 One study involving over-utilization of treatments found a correlation
between density of attorneys in a given area and the likelihood of over-prescription of
medications. 95 Finally, doctors are hesitant to change their ways, and they value autonomy of
decision making. 96
These factors coupled together demonstrate that the current state of comparative
effectiveness research as authorized by the PPACA is likely to accomplish little in the way of
care outcomes or cost savings. The program as it now exists will spend a great deal of money to
provide a large amount of valuable data that, without proper implementation, will likely fall on
deaf ears of health care professionals.
While comparative effectiveness research as currently implemented in the U.S. will likely
have little impact, comparative research is being used widely abroad to provide better, more
efficient care. 97 Part IV of this Comment will explore the United Kingdom's use of comparative
effectiveness. The United Kingdom possesses one of the most established and longest running
implementations ofHTA. The United States can, and should, use the structuring of this system,
its benefits, and its downsides to create a more beneficial system in America.

the treatment's ineffectiveness. This was attributed to patient demand, driven by anecdotal evidence of what patients
had heard in support groups or from information disseminated from insurance companies.).
94
Emanuel, supra note 91, at 2790 ("Medical malpractice laws and the resultant defensive medicine also contribute
to overutilization [of health care]").
95
George Sakoulas, Relationship Between Population Density ofAttorneys and Prevalence of Methicillin-Resistant
Staphylococcus Aureus: Is Medical-Legal Pressure on Physicians a Driving Force Behind the Development of
Antibiotic Resistance?, 16 AM. J. OF THERAPEUTICS I, 6 (Using attorney density in a area as a surrogate for medical
malpractice likelihood, this study hypothesized that medications, in particular anti-biotics, are over-prescribed by
p,hysicians out offear that if they fail to prescribe, they run a greater risk of being sued).
6
Mark Miller, Remarks at the Public Meeting of the Medicare Payment Advisory Commission 107 (Sept. 17,
2009), available at http://www.medpac.gov/transcripts/0909MedPAC.pdf. A Medicare Payment Advisory
Commission found that doctors do not like to change practice unless they have to. !d. "Personal experience" with a
treatment was often enough to make treatment decisions. One physician was quoted as saying "We have our
judgment, If we like something, if it works, great. !fit doesn't, then we try something else." ld.
97
See INTERNATIONAL PROFILES OF HEALTH CARE SYSTEMS, THE COMMONWEALTH FUND JUNE 20] 0, available at
http://www .commonwealthfund.org/Publications/Fund-Reports/20 I 0/Jun/Intemational-Profiles-of-Health-CareSystems.aspx (describing comparative effectiveness research system in use in such countries as the United
Kingdom, France, Italy, Canada, Germany, and Australia).
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IV. Comparative Effectiveness Research in the United Kingdom
Statutory authorization for the use of comparative effectiveness research in the approving
of or paying for medical treatments is not new to Europe and other parts of the world. 98 The
United Kingdom has a nationalized health care system where all people "ordinarily resident" in
the country are entitled to predominantly free health care. 99 The United Kingdom National
Health Service (NHS)Ioo established the National Institute for Health and Clinical Excellence
(NICE) for the purpose of making recommendations for coverage to the NHS in regards to new
and existing medicines and treatments.IOI The NHS is legally obligated to provide funding for
pharmaceuticals recommended by the NICE.I 02
The NICE's focus when recommending treatments is not merely on clinical effectiveness
but also factors in the cost of health care technologies.I 03 This model uses a cost-benefit system
of analysis, I04 relying heavily on cost analysis using quality-adjusted life years (QALY). 105
QAL Y is calculated by finding the current quality of life of a patient and examining any increase
or decrease in quality of life and length of life that a new treatment may offer.I 06 Although each
drug or treatment is considered on a case-by case basis, generally "if a treatment costs more than
£20,000 to £30,000 per QAL Y, it will not be considered cost effective."I 07

Id.
National Health Service Regulations, 1948, 15 & 16 Geo. 6, § 1483 (Eng.); see also INTERNATIONAL PROFILES OF
HEALTH CARE SYSTEMS, THE COMMONWEALTH FUND JUNE 20 l 0, available at
http://www .commonwealthfund.org!Publications/Fund-Reports/20 I 0/Jun/International-Profiles-of-Health-CareSystems.aspx
100
National Health Service, 1999, c. 220 (U.K.).
101
ld; see also Measuring Effectiveness and Cost effectiveness: the QALY, NAT'L INST. FOR HEALTH AND CLINICAL
EXCELLENCE, available at http://www.nice.org.uklnewsroom/features/ (last updated Apr. 20, 2010).
measuringeffectivenessandcosteffectivenesstheqaly.jsp
102
National Health Service, 1999, c. 220 (U.K.).
103
International Profiles of Health Care Systems, supra note 95.
104
See discussion supra Part II.
105 Id.
106
Measuring Effectiveness and Cost effectiveness: the QALY, supra note 102.
101 Id.
98

99
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Many consider the NICE an international role model for the implementation of cost
effectiveness in health care systems. 108 The belief is that the United Kingdom is an innovator,
taking the steps to curb costs that most other health care systems will be forced to take in the
future. 109 However, others have harshly criticized the NICE and its drastic use of QALY. 110
Frequently, the NICE has issued guidance restricting the use of new medications that were found
to be too expensive, based on a QALY analysis. 111 The system is criticized as being overly
formulaic and rigid without allowing for adaptation to the clinical problem at hand. 112 Although
used as a tool for health care systems to battle costs, some cite flaws, such as subjectivity and
arbitrariness, inherent in a QAL Y-based system. 113 In addition, because the most costly drugs
are often the ones which are used to treat the sickest patients, the NICE's decisions are further
thrust into the firing line. For example, the NICE has controversially rejected treatments for
cancer patients because the costs were deemed too high. 114 Cost-cutting care decisions such as
these have led to a criticism that the United Kingdom has essentially instituted a system of
"death panels" which sentence the sick to a lack of care simply due to costs. 115 Thus, the duality
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!d. See generally CORINNA SORRENSON ET AL., NICE: HOW DOES IT WORK AND WHAT ARE THE IMPLICATIONS
FOR THE U.S.? (2008).
109
Sorrenson, supra note 106.
110
Paul Eastman, Does NICE have to be Cruel to be Kind?, THE TELEGRAPH, Oct. 30, 2006,
http://www.telegraph.co.uklhealth/3344366/Does-Nice-have-to-be-cruel-to-be-kind.html; Emma Wilkinson, Talk
NICE around the Globe, BBC NEWS, Feb. 16, 2009, http://news.bbc.co.uk/2/hilhealth/7830744.stm (discussing how
a series of controversial treatment denials let to outcry and protest from British citizens).
111
See MICHAEL SCHLANDER, COMPARATIVE EFFECTIVENESS PROGRAMS: A GLOBAL PERSPECTIVE (GALEN ]NST.
2009).
112 !d.
113

John Wyatt, What"s Wrong with Quality of Life as a Clinical Tool?. 7 AM. MED. Ass'N J. ETHICS 2 (2005)
(arguing that QALY measurements are not as internationally recognized and universally agreed upon as the United
Kingdom would make them out to be).
114
Zosia Chustecka, UK NICE Rejects 3 Drugs for Metastatic Colorectal Cancer, MEDSCAPE.COM (Sept. 6, 20 II),
http://www.medscape.com/viewarticle/749150. Avastin, Erbitux and Vectibix, three medications for colorectal
cancer, were rejected in 20 II because the cost, upwards of£ 150,000 per QALY gained, was deemed too high to
justify the benefits. !d. Note that these medications are approved for payment by Medicare in the United States.

!d.
115

See. e.g., Sophie Borland, The Breast Cancer Patients TOO OLD To Save: Thousands Are Being Denied Surgery
By 'Ageist" Doctors, THE DAILY MAIL (June 16, 2011, 2:52PM), http://www.dailymail.co.uk/health/article2004040/Breast-cancer-Thousands-denied-life-saving-surgery-doctors-base-treatment-age.html#ixzz I kCuTcFir
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of the comparative effectiveness in the United Kingdom is striking: QALY has been used to save
billions of pounds a year, 116 but the controversy that the QALY system has brought with it has
been great. 117
V. Reforming Comparative Effectiveness Research in the United States: Meshing
American Sensibilities with the Need for Change
As already discussed, the current implementation of comparative effectiveness research
in the United States will likely produce little impact. 118 Development of data is worthless
without fostering a system that translates evidence into action. 119 However all is not lost. By
integrating what has been learned from the implementation of comparative effectiveness research
in the United Kingdom with the needs of the American system, there is room to provide more
clinically efficient care while still respecting the value of human life.
While the current implementation of comparative effectiveness research in the United
States will likely produce little result, the solution is not to directly ration access to
pharmaceuticals and treatments, as is being done in the United Kingdom, as this is likely not a
proper fit for America. 120 Limiting access to pharmaceuticals, even minimally, is an extremely

(stating that 15,000 elderly die prematurely every year because cancer care on the NHS is not as good as that
provided elsewhere in Europe and the United States); Denis Campbell, Patients Denied Key Treatments Due To·
NHS Cost-cutting. Surgeons Warn, THE GUARDIAN, Apr. 18,2011, http://www.guardian.co.uk/society/2011/apr/18/
nhs-cost-cutting-surgeon-warning (stating that surgeons in the United Kingdom worry that key procedures are
unfairly being label as having limited clinical value due to cost-cutting measures).
116
Nicholas Timmons, Letter From Britain: Across The Pond, Giant New Waves Of Health Reform, 29 HEALTH
AFFAIRS 12 (2010) (estimating that the QALY based system has been used to save the United Kingdom upwards of
£20 billion a year).
117
Id. (noting that public protests in the United Kingdom against austerity measures, such as the use ofQALY, are
not an infrequent occurrence).
118
See supra Part IV.
119
Saver, supra note 63, at 2156.
120
See, e.g., Peter Neumann & Dan Greenberg, Is The United States Ready For QALYs?, 5 Health Affairs 3l("Strict
adherence to a QALY approach is likely to prove unacceptable in the United States."); How the UK Rations Health
Care, PUBLIC RADIO INTERNATIONAL (Dec. 17,2010, 9:24AM), http://www.pri.org/stories/health/how-the-ukrations-health-care.htrnl (stating that rationing, even though controversial in the United Kingdom, would meet an
exponentially colder reception in the United States. This is premised on the idea that in the United Kingdom
"rationing [has] become a part of the national identity" due to the history of citizens sacrificing for the nation,
reaching back to rationing of food and gasoline during World War II).
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thorny issue in the United States that has already garnered much controversy. 121 There are
already rampant fears that comparative effectiveness research will lead to "death panels," 122 a
somewhat Orwellian concept where the ill would be forced to go before tribunals in order to
have funding approved or denied for their health care. 123
Even the short-lived Federal Council as established by the ARRA stimulus plan was
maligned and often mischaracterized. 124 For example, the Wall Street Journal mischaracterized
the plan as stipulating that certain medications "will no longer be prescribed." 125 However,
much of the fervor today is likely due to a misunderstanding of the complicated legislation or,
unfortunately, an outright misstatement of what the PCORI is authorized to do. 126 Many have
already confounded the NICE system of the United Kingdom with the legislation as enacted in
the United States. 127

121

See, e.g., Alan S. Gerber et al., A National Survey Reveals Public Skepticism About Research-Based Treatment
Guidelines, 29 HEALTH AFF. 1882 (2010).
"'Id.
123
Obama Embraces "Death Panel Concept in Medicare, NEWSMAX (Dec. 26, 2010 6:41PM),
http://www .newsmax.com/Headline/obama-death-panels-medicare/20 l 01!2/26/id/3 8 I 04 3; Rachel Weiner, P a/in:
Obama's "Death Panel" Could Kill My Down Syndrome Baby, THE HUFFINGTON POST, May 25, 201 I,
http://www.huffingtonpost.com/2009/08/07/palin-obamas-death-panel_n_ 254399.html (discussing how the once
presidential hopeful Sarah Palin claimed that PPACA would institute "death panels." Her claim was that those with
illnesses such as down syndrome would be forced to "stand in front ofObama's 'death panel' so his bureaucrats can
decide, based on a subjective judgment of their 'level of productivity in society,' whether they are worthy of health
care. Such a system is downright evil").
124
See, e.g., Alicia Mundy, Drug Makers Fight Stimulus Provision, WALL ST. J. (Feb. 10, 2009),
http://online. wsj .com/article/SB l2342302420396608l.html
125
!d. But see WSJ Falsely Suggested That Comparative Effectiveness Research Provision in House Bill Dictates
Certain Treatments "Will No Longer Be Prescribed", MEDIA MATTERS FOR AMERICA, Feb. I I, 2009,
http://mediamatters.org/research/2009021 10026 (correctly stating that the provision was not a part of the Federal
Council authorization).
126
Kativa Patel, Health Reform's Tortuous Route To The Patient-Centered Outcomes Research Institute, 3 I Health
Affairs 1777, 1778 (stating that media overgeneralizations about PCORJ and comparative effectiveness research
have led some to distrust the system without actually understanding it).
127
See David Catron, How Much is a Year of Your Life Worth?, AMERICAN SPECTATOR (July 24, 2009, 6:09AM),
http://spectator.org/archives/2009/07/24/how-much-is-a-year-of-your-lif ("This new bureaucracy ... will assign a
monetary value to your life and deny your care if you contract a malady whose cost-of-treatment exceeds that
amount.") In reality, the PCORJ is not authorized to take into account QALYin any part of the legislation. Martin
Feldstein, ObamaCare Is All About Rationing, WALL ST. J., Aug. 19, 2009, at AI5 ("rationing health care is central"
to the new strategy to reduce health care costs).
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While the talk of"death panels" is vastly over-stated, it must be noted that to properly
implement a working system of comparative effectiveness research there are valid concerns that
must be addressed, as a system based on this type of research has the potential to contain great
flaws. Of foremost importance is the concern that comparative effectiveness research by nature
cannot adequately take into account individual patient differences. 128 There is also a risk of
overbroad characterization of certain treatments or medications. 129 Treatments may be defined
as "the same" when in fact the goals that they serve are different but in a nuanced way. 130 As
such, an aggressive, rigid system such as that of the United Kingdom is not the best way to
minimize these problems. What is best is a system which starts out based on conservative use
comparative clinical effectiveness 131 and then builds on the practical knowledge that is gains
from real world use.
In order to assuage public fears and also limit potential complications from a rushed or
improper implementation of a comparative effectiveness system, this Comment proposes that
America start slow. For certain types of care, cost effectiveness included in comparative
effectiveness research may not be the best fit. End-of-life care, while expensive, 132 is the
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Saver, supra note 63, at 2155 ("[P]hysicians may rightly be concerned that a particular [comparative
effectiveness research] study did not include subjects truly representative of their own patients.").
129
!d. at 2157.
130 !d.
131
Miller, supra note 94 (quoting Thomas Dean, Medicare Payment Advisory Commissioner: "We are never going
to have perfect data. There's always going to be patients who have unique situations, and we have to make sure our
policies allow for that, and that if we make good clinical decisions that don't entirely follow [the results of
comparative effectiveness research], there has to be an allowance for that").
132
Centers for Medicare and Medicaid Services, Decision Memo for Autologous Cellular Immunotherapy Treatment
of Metastatic Prostate Cancer, June 30, 2011, available at http://www.cms.gov/medicare-coveragedatabase/details/nca-decision-memo.aspx?NCAid~247&veF12&caNarne~

Autologous+Cellular+Immunotherapy+Treatment
+of+Metastatic+Prostate+Cancer&TimeFrame~? &DocType~All&bc~ AgAA YAAAIAAA&.

Medicare approved
Provenge, a treatment for prostate cancer that costs $93,000 per patient. !d. See also Courtney Hutchinson,
Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?, ABC NEWS (July 29, 2010),
http://abcnews.go.com!Health/ProstateCancerNews/provenge-cancer-vaccine-months-life-worth- I OOk
/story?id~11269159 (stating that while Provenge has been shown to extend the life of the patient for only four
months, one reason for the expense of cancer treatments is that because they are traditionally covered by insurance

and cost effectiveness is not taken into account by insurance companies, drug manufacturers can charge inflated
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thorniest type of care to address. QAL Y analysis, as has been strictly applied in the United
Kingdom is not as clear cut as it seems. 133 What constitutes the value or enjoyment of life is the
subject of countless articles and books. 134 Even ignoring all moral grounds, from simply a
strategic standpoint, attempting to tackle cost cutting by addressing end-of-life care would only
give validity to the claims of "death panels" and care rationing that opponents of comparative
effectiveness research have clamored over. 135 This would almost certainly sink the comparative
effectiveness research ship before it even had a chance to leave port.
However, end-of-life care is but one portion of growing medical costs. The American
health care system is ripe with the "low hanging fruit" of routine procedures and medications for
non-life threatening illness that are not clinically proven but still routinely prescribed. 136 If the
United States starts by addressing uncontroversial yet costly care, use of comparative
effectiveness research has a chance of making a foothold in the United States.
A potential place to start would be by taking a closer look at certain types of "me-too"
medications. A "me-too" medication is a class of drugs for which there are multiple variants,
each containing a slightly modified version of the active ingredient. 137 Technically different
molecules, the production of these medications is an easy way for drug manufacturers acquire

prices for treatments); Scott Hensley, Debate Over Value ofProvenge Boils over on Medicare Site, NPR (Aug. 8,
20 10), http://www .npr.org/blogs/health/20 I 0/08/02/12893 0253/provenge-medicare-coverage-comments (discussing
the battle between proponents for providing end-of-life care regardless of cost and those in favor of cutting end-oflife care that potentially adds little "value" to patients' lives).
133
See Wyatt, supra note Ill.
134
See, e.g., COST-EFFECTIVENESS IN HEALTH AND MEDICINE (Martha Gold et al. eds., 1996); PETER A. UBEL,
PRICING LIFE: WHY IT'S TIME FOR HEALTH CARE RATIONING (1999); JOHN MCKIE, THE ALLOCATION OF HEALTH
CARE RESOURCES: AN ETHICAL EVALUATION OF THE 'QALY' APPROACH (1998); ANDREW EDGAR ET AL., THE
ETHICAL QALY: ETHICAL ISSUES IN HEALTHCARE RESOURCE ALLOCATIONS (1998).
135
See discussion supra note 120.
136
See supra notes 2-{); see also Alexandra Kirkley, A Randomized Trial ofArthroscopic Surgery for Osteoarthritis
of the Knee, 359 NEW ENG. J. 1097 (2005) (finding that arthroscopic knee surgery failed to show any benefit to
conventional physical therapy); R. Eugene Bailey, Arthroscopic Surgery Ineffective for Osteoarthritis of the Knee,
51 J. FAM. PRACTICE 10 (2006).
137
Joshua Gange, How Many "Me-too" Drugs is Too Many?, 305 JAMA 152 (2011).
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lucrative new patents. 138 For example, proton pump inhibitors (PPis) are a category of drugs
which are used to treat gastroesophageal reflux disease, commonly known as heartburn. 139
Nexium, a PPI, is in the top ten of all prescriptions within the United States 140 with sales topping
$8 billion in 2010. 141 Nexium shares market space with many other PPis, a group of drugs that
are generally considered chemically equivalent. 142 "Nexium is no more effective than Prilosec"
said Sharon Levine, an executive with Kaiser Permanente, the largest health maintenance
organization in the United States. 143 "I'm surprised anyone has ever written a prescription for
Nexium." 144 Nexium can cost over $200 a month, but is the equivalent to Prilosec, a medication
sold over the counter without need for a prescription. 145 Prilosec costs roughly $15 a month. 146
They are both made by the same company, AstraZenica. 147
Starting with a small class of drugs, such as "me-too" drugs, and shining a light on the
inefficiencies inherent in their use, has incredible potential for driving change. Not only will it
save money directly by moving patients towards use of drugs that are still clinically effective but
cheaper than others on the market, it has the potential to ease the public and health care providers
into further acceptance of comparative effectiveness research. Even more, the money that is
saved may help reduce the burden on the health care system, and thus foreclose the need to make

!d.
Proton Pump Inhibitors, HEARTBURN.COM, http://www.heartburn.com/ReliefAndManagement/PPI.aspx. (last
visited Feb. 9, 2012).
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Stuart Elliot, Prescription Drug Ads Come Under Criticism, N.Y. TIMES, Oct. 13, 2004,
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difficult decisions about expensive end-of-life care in the future. This is directly counter to what
people fear will happen with "death panels."
This slow and easy start to using comparative effectiveness research in the United States
further holds the potential to not only drive down health care costs but also to drive greater
innovation. It is extremely expensive to produce innovative drugs, but much cheaper to produce
"me-too" drugs. 148 In 2004, 75% of the drugs that the FDA approved were classified as similar
to existing ones on the market in either chemical makeup or therapeutic value.

149

Marcia Angell,

former editor-in-chief of the New England Journal of Medicine, stated that "over the past two
decades [the drug industry] has moved very far from its original pnrpose of discovering and
producing useful new drugs." 150 She claims that the pharmaceutical companies are now
"primarily ... marketing machine(s) that sells drugs of dubious benefit. 151 By being able to
produce profitable "me-too" medications, pharmaceutical companies have less incentive to
invest in research and development for novel and potentially more needed drugs. 152
The FDA cannot take into account cost effectiveness when approving drugs to market. 153
With Medicare and PCORI hamstrung by legislation from effectively taking into account cost
effectiveness or relative therapeutic value of drugs, pharmaceutical companies have little
incentive not to spend money on marketing campaigns for recycled drugs rather than striving for
148
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Summer 2005, available at http://stanmed.stanford.edu/2005summer/drugs-metoo.html.
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150
See ANGEL, supra note 90.
151
Jake Whitney, Pharmaceutical Sales 101: Me-Too Drugs, GUERNlCA MAG, Feb. 2006, available at
http://www.guernicamag.com/featureslllllme_too_drugs/ (discussing how many physicians and academics feel that
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new innovative treatments. 154 This Comment does not argue that the FDA should ban safe and
effective drugs from authorization in the United States simply because they might not be costeffective. 155 However, by having Medicare, the largest insurance payer in the United States, look
closely at the relative clinical effectiveness of medications, drug manufacturers will maintain
incentives to spend their funds on new drug innovation. By moving manufacturers away from
recycling drugs with new patents, the benefits for approving a new drug for payment in the same
medication class become less and less. 156
By having Medicare take into account comparative clinical effectiveness, an added
incentive is that it will not only legitimize the practice for additional use by private insurance
companies, it will actually push them to use it. Medicare makes decisions that "profoundly
affect ... the cost-benefit calculations and policy decisions of ... [private] insurers." 157
Medicare provides health coverage to one out of every seven Americans. 158 Its reimbursement
and coverage policies are widely adopted by private insurers and other public programs. 159 Since
private insurers are driven by Medicare as the first mover, mandating that for certain procedures
or medications Medicare must take into account cost effectiveness will push the private side to
do the same. 160
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VII. Conclusion

"No publically funded health care system ... can possibly pay for every new medical
treatment ... choices have to be made." 161 While it may be somewhat unsettling to envision a
system where health care choices are made with view towards economy, this statement bluntly
describes the realities that health care systems, both public and private, face in countries across
the globe. With health care costs rising every year, 162 something must be done to curb spending.
Comparative effectiveness research is unique in that it holds the promise of cutting costs
while actually increasing health outcomes. 163 While some countries like the United Kingdom
have used comparative effectiveness to ration care, 164 comparative effectiveness research is more
accurately framed in a different light. At its foundation is not the rationing of care, but actually
the providing of better care. 165 The best promise for comparative effectiveness research to make
a difference in America is to use it to weed out expensive, redundant, or unfruitful treatments so
patients can get the right treatment. Cost effectiveness is an added benefit to, and inherently
flows from, providing proper, effective treatments to patients. If you provide people with the
proper care, not just the newest or most expensive care, people will be healthier, use less of the
resources ofthe health care system, and in tum the system will save money.
Although comparative effectiveness research has been maligned due to fear of care
rationing and "death panels," 166 if the United States implements the system the right way, it can
foster a better understanding of what comparative effectiveness research actually means.
161
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Garnering doctor, patient, and political support for this system is essential if a difference is to be
made in the health care system. While comparative effectiveness research carries with it very
real potential downsides, if implemented with an eye towards caution, these downsides can be
avoided. 167
Thus, the translation of research data to clinical outcomes should start slowly.
Treatments that involve end-of-life care or lifesaving procedures are undoubtedly expensive, but
starting a comparative effectiveness program that attacks this end of the health care cost
spectrum is unwise. There is much to be saved on the other end ofthe spectrum, by starting to
take action with routine, everyday medications and procedures. By starting with low-level
medications that treat non-life threatening illnesses, we can make a smart, sensible change in the
way medications and treatments are prescribed. This will garner support for comparative
effectiveness research, lower health care cost, drive pharmaceutical innovation and create a
healthier populace.
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See discussion supra Part VI.
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